Chronic Inflammatory Demyelinating Polyradiculoneuropathy – An Overview of Existing Treatment
87. Mahattanakul W, Crawford TO, Griffin JW, et al., Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A, J Neurol Neurosurg Psychiatry 1996;60:185–7.
88. Hodgkinson SJ, Pollard JD, McLeod JG, Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy, J Neurol Neurosurg Psychiatry, 1990;53:327–30.
89. Gorson KC, Natarajan N, Ropper AH, Weinstein R, Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial, Muscle Nerve, 2007;35:66–9.
90. Briani C, Zara G, Zambello R, Trentin L, et al., Rituximab-responsive CIDP, Eur J Neurol, 2004;11:788.
91. Knecht H, Baumberger M, Tobon A, Steck A, Sustained remission of CIDP associated with Evans syndrome, Neurology, 2004;63:730–2.
92. Sadnicka A, Reilly MM, Mummery C, et al., Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis, J Neurol Neurosurg Psychiatry, 2011;82:230–2.
93. Benedetti L, Franciotta D, Beronio A, et al., Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura, Muscle Nerve, 2008;38:1076–7.
94. Benedetti L, Briani C, Franciotta D, et al., Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature, J Neurol Neurosurg Psychiatry, 2010; [Epub ahead of print].
95. Hirst C, Raasch S, Liewelyn G, Robertson N, Remission of CIDP after alemtuzumab, J Neurol Neurosurg Psychiatry, 2006;77:800–2.
96. Marsh EA, Hirst CL, Llewelyn JG, et al., Alemtuzumab in the treatment of IVIg-dependent chronic inflammatory demyelinating polyneuropathy, J Neurol, 2010;257:913–9.
97. Chin RL, Sherman WH, Sander HW, et al., Etanercept (Enbrel®) therapy for chronic inflammatory demyelinating polyneuropathy, J Neurol Sci, 2003;210:19–21.
98. Richez C, Blanco P, Lagueny A, et al., Neuropathy resembling CIDP in patients receiving tumor necrosis factor- alpha blockers, Neurology, 2005;64:1468–70.
99. Alshekhlee A, Basiri K, Miles JD, et al., Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists, Muscle Nerve, 2010;41:723–7.
100. Ahlmen J, Andersen O, Hallgren G, Peilot B, Positive effects of tacrolimus in a case of CIDP, Transplant Proc, 1998;30:4194.
101. De Weerdt A, Claeys KG, de Jonghe P, et al., Tacrolimus- related polyneuropathy: case report and review of the literature, Clin Neurol Neurosurg, 2007;110:291–4.
102. Echaniz-Laguna A, Anheim M, Wolf P, et al., Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in patients with solid organ transplantation: a clinical, neurophysiological and neuropathological study of 4 cases, Rev Neurol (Paris), 2005;161:1213–20.
103. Labate A, Morelli M, Palamara G, et al., Tacrolimus-induced polyneuropathy after heart transplantation, Clin Neuropharmacol, 2010;33:162.
104. Wilson JR, Conwit RA, Eidelman BH, et al., Sensorimotor neuropathy resembling CIDP in patients receiving FK506, Muscle Nerve, 1994;17:528–32.
105. Villa AM, Garcea O, Di Egidio M, et al., Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report, Arq Neuropsiquiatr, 2004;62:892–4.
106. Choudhary PP, Thompson N, Hughes RAC, Improvement
following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy, J Neurol, 1995;242: 252–3.
107. Cocco E, Mamusa E, Carboni N, et al., Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon beta-1B, J Neurol, 2005;252: 1420–2.
108. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al., Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy, Neurology, 1999;53:1364–5.
109. Vallat JM, Hahn AF, Léger JM, et al., Interferon beta-1a as an investigational treatment for CIDP, Neurology, 2003;60: S23–S28.
110. Hughes RA, Gorson KC, Cros D, et al., Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy, Neurology, 2010;74:651–7.
111. Pirko I, Kuntz NL, Patterson M, et al., Contrasting effects of IFN{beta} and IVIG in children with central and peripheral demyelination, Neurology, 2003;60:1697.
112. Matsuse D, Ochi H, Tashiro K, et al., Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferon beta-1b therapy in a patient with childhood-onset multiple sclerosis, Intern Med, 2005;44:68–72.
113. Gorson KC, Ropper AH, Clark BD, et al., Treatment of chronic inflammatory demyelinating polyneuropathy with inteferon alpha-2a, Neurology, 1998;50:84–7.
114. Ueda M, Ota K, Takeuchi M, et al., Treatment with interferon-alpha 2a in a patient with chronic inflammatory demyelinating polyneuropathy, Rinsho Shinkeigaku, 2000;40:155–9.
115. Gorson KC, Allam G, Simovic D, Ropper AH, Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy, Neurology, 1997;48:777–80.
116. Pavesi G, Cattaneo L, Marbini A, et al., Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy, J Neurol, 2002;249:777–9.
117. Hirotani M, Nakano H, Ura S, et al., Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha, Intern Med, 2009;48:373–5.
118. Bassetti BR, Trés ES, Ciríaco JG, Pinto Neto LF, Chronic inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alpha 2b in a patient with HIV/HCV coinfection: case report, Rev Soc Bras Med Trop, 2010;43:89–91.
119. Vermeulen M, Van Oers MH, Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy, J Neurol Neurosurg Psychiatry, 2002;72:127–8.
120. Oyama Y, Sufit R, Loh Y, et al., Nonmyeloablative autologous hematopoietic stem celltransplantation for refractory CIDP, Neurology, 2007;69:1802–3.
121. Reményi P, Masszi T, Borbényi Z, et al., CIDP cured by allogeneic hematopoietic stem cell transplantation, Eur J Neurol, 2007;14:e1–e2.
122. Mahdi-Rogers M, Hughes RAC, Kazmi M, Ferner R, Autologous peripheral blood progenitorcell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy, J Periph Nerv Syst, 2007;12(S):55.
123. Mahdi-Rogers M, Kazmi M, Ferner R, et al., Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy, J Periph Nerv Syst, 2009;14:118–24.
124. Vermeulen M, Van Oers MH, Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation, J Neurol Neurosurg
Psychiatry, 2007;78:1154.
125. Peters G, Larner AJ, Chronic inflammatory demyelinating polyneuropathy after autologous peripheral blood stem cell transplantation, J Periph Nerv Syst, 2005;10:384–5.
126. Kapoor S, Wilson AG, Sharrack B, et al., Haemopoietic stem cell transplantation—an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology, neurology and gastroenterology, Hematology, 2007;12:179–91.
127. Iijima M, Yamamoto M, Hirayama M, et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP, Neurology, 2010;64:1471–5.
128. Gardulf A, Andersen V, Bjorkander J, et al., Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs, Lancet, 1995;345: 365–9.
129. Köller H, Schroeter M, Feischen H, et al., Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies, J Neurol, 2006;253:1505–6.
130. Lee DH, Linker RA, Paulus W, et al., Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy, Muscle Nerve, 2008;37:406–9.
131. Eftimov F, Vermeulen M, de Haan RJ, et al., Subcutaneous immunoglobulin therapy for multifocal motor neuropathy, J Periph Nerv Syst, 2009;14:93–100.
132. Harbo T, Andersen H, Hess A, et al., Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomised, single-blinded cross-over trial, Eur J Neurol, 2009;16:631–8.
133. Jung S, Toyka KV, Hartung HP, Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats, Neurosci Lett, 1995;200:167–70.
134. De Jonge RR, van Schaik IN, Vreijling JP, et al., Expression of complement components in the peripheral nervous system, Hum Mol Genet, 2004;13:295–302.
135. De Jonge RR, Vreijling JP, Meintjes A, et al., Transcriptional profile of the human peripheral nervous system by serial analysis of gene expression, Genomics, 2003;82:97–108.
136. Ramaglia V, Wolterman R, de Kok M, et al., Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury, Am J Pathol, 2008;172:1043–52.
137. Ramaglia V, Daha MR, Baas F, The complement system in the peripheral nerve: Friend or foe?, Mol Immunol, 2008;45:3865–77.
138. Ramaglia V, King RH, Nourallah M, et al., The membrane attack complex of the complement system is essential for rapid Wallerian degeneration, J Neurosci, 2007;27:7663–72.
139. Halstead SK, Zitman FM, Humphreys PD, et al., Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model, Brain, 2008;131:1197–208.
140. Willison HJ, Halstead SK, Beveridge E, et al., The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome, J Neuroimmunol, 2008;201–202:172–82.
141. Hughes RAC, Allen D, Makowska A, Gregson NA, Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy, J Periph Nerv Syst, 2006;11:30–46.
142. Meyer zu Hörste G, Hartung HP, Kieseier BC, From bench to bedside—experimental rationale for immune-specific therapies in the inflamed peripheral nerve, Nat Clin Pract Neurol, 2007;3:198–211.
143. Köller H, Kieseier BC, Jander S, Hartung HP, Chronic inflammatory demyelinating polyneuropathy, N Engl J Med, 2005;352:1343–56.
EUROPEAN NEUROLOGICAL REVIEW
51
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76